• Our News

A potentially revolutionary new technology – that could saves thousands of lives in Intensive Care Units around the world – is being trialled in a UK study co-led by Queen’s University.

Covering 1,120 critically ill patients in 40 different sites in Britain and Northern Ireland over five years, the research project will test a new strategy designed to minimise damage to the lungs caused by mechanical ventilation – commonly referred to as ‘ventilators’. The study will be one of the largest clinical trials in the world, to date, involving patients with respiratory failure.

The National Institute for Health Research (NIHR) has funded the £2.1 million research which will be jointly led by Queen’s and Belfast Health and Social Services Trust.

Respiratory failure is common in the UK; about 100,000 people each year require the assistance of ventilators in ICUs and up to 40 per cent of these patients die. The number of deaths exceeds that from road traffic accidents or from prostate cancer and leukaemia combined.

Although there is evidence that ventilators save lives, they can also be associated with damage to the lungs, because of the mechanical pressure exerted on the organs.

Now, a new type of technology called ‘extracorporeal carbon dioxide removal’, which aims to facilitate a gentler type of ventilation, offers the hope that more lives could be saved, but only a clinical trial, such as the one being co-led by Queen’s, will provide definitive results.

Professor Danny McAuley, Professor of Intensive Care Medicine at the Centre for Infection and Immunity at Queen’s University Belfast, explained: “A mechanical ventilator acts like bellows as air is forced into the lungs under pressure. If the pressure is too high, this can cause lasting damage. But we are hoping that this new technology will help us ventilate the lungs more gently. That is because these new devices have been designed to help remove carbon dioxide from the patient’s blood – in a process quite similar to kidney dialysis – which is one of the main functions of the lungs.

“The new technology involves a catheter being inserted into the patient’s vein. Blood from the patient then passes through a device where it is ‘washed’ to remove carbon dioxide before being returned to the patient. By temporarily removing some of this function from the lungs, it means they do not have to do as much work as usual, and so a gentler ventilation may be sufficient, easing the pressure on them.”

Dr James McNamee, from Belfast Health and Social Care Trust said: “In our study, there will be two groups of people admitted to ICUs with respiratory failure. One will receive the best level of care within current NHS guidelines while the other group will have the additional, new treatment to artificially remove the carbon dioxide from their blood. At the end, we should know whether the new technology can impact on mortality rates.

“We can also begin to look at the long-term survival and quality of life for patients treated with this technology, as well as the cost implications click reference. The fact is, even patients who survive respiratory failure often suffer long-term health problems. As well as impacting on quality of life, these knock-on problems are a significant drain on resources in the NHS so anything we can do to improve outcomes would be a win-win situation.”

The extracorporeal CO2 removal device to be used in the study, called the Hemolung Respiratory Assist System, is manufactured by US-based ALung Technologies. Peter DeComo, Chief Executive Officer of ALung said: “We are honoured to have been chosen by the study team as the technology partner for this very important project. This study promises to provide the most robust evidence yet regarding the impact of minimally invasive extracorporeal CO2 removal technology to reduce mortality through facilitation of an ‘ultraprotective’ ventilation strategy. We thank Professor McAuley and his team for their efforts to organise this landmark study and look forward to its commencement.”

Dr Janice Bailie, Assistant Director of the Public Health Agency’s Health and Social Care R&D Division in Northern Ireland, which has provided long-term support to help this team secure the award said: “I am delighted that Northern Ireland will lead this UK-wide research study that has the potential to improve the management of patients in critical care worldwide. The prestigious National Institute for Health Research offers the opportunity for local researchers like Professor McAuley and his team to bring major research income to Northern Ireland, to support this type of study. The results of this study will be of interest at an international level and will highlight the capability of Northern Ireland researchers to lead globally significant healthcare research”.

Source: http://www.qub.ac.uk/home/ceao/News/#d.en.541200


For any small business, one of the most critical ingredients for growth is partners. The right suppliers, distributors, retailers, and specialists can broaden your reach and capabilities. But winning over established companies is a major challenge for small companies, especially newer ones. “You have to prove you’re for real,” says Ian Rosenberger, the CEO of five-year-old Thread International.

A former MTV host and founder of a video production company, he traveled to Haiti following the devastating 2010 earthquake and started Thread, a fabric company with an ambitious social mission. The business turns that country’s abundant plastic trash into what Rosenberger calls “the most responsible fabric on the planet,” boosting the local economy with new jobs and revenue.

Thread is convincing apparel giants, fabric manufacturers, VCs, and others to take a chance on a promising unknown. Here, Rosenberger shares with Spark Business IQ his keys to landing strategic partners.

1. Know when to stop developing and start selling

The turning point is when you know someone wants your product. Until then, you keep developing and developing, and all the talk about your selling message and PR is just talk.

One of the best pieces of advice I got on this was from someone at a big denim company who said, “I can make the most environmentally responsible denim on the planet. But if their ass doesn’t look good in the jeans, people aren’t going to buy it.” That’s it: If you have a great product, you’ll attract customers.

And that’s where we are. We know we have a product worth selling. So 80 percent of our time now is spent getting in front of customers, and 20 percent is spent developing new things that will make us attractive to the customers we’ll have three years from now.

2. Earn credibility one test at a time

In the beginning, everybody wants to know, “Can you deliver what you say you can deliver?” For us, it’s making a fabric that’s as good as we say it is. The last question we get is always, “How many employees do you have?” When we tell them, their response is, “No way. We’re a $500 million company. How can a company with five people do this?”

There’s a great deal of having to jump through hoops and over bars and go above and beyond what you’d normally do. Companies are holding you to a higher standard. When there’s a deadline, we hit it or deliver early. If there’s a quality issue, we respond in a way that makes the experience better than if there had been no issue at all. They realize we’re in it to win.

3. Understand what matters to your partners

You know that saying: There’s speed, quality, and price, and if you win on two of those, you get the business every time sertraline hcl 50 mg. We’ll buy what a company is currently using, take it apart, and do a life-cycle analysis on the social and environmental impact. We make comparison cards to show that if you replace your fabric with ours, here’s how it’s better in CO2, water, pesticides, and the economic impact on a community. At times, we’ve also unearthed how we’re cheaper than the organic cotton they’re using. That changes the conversation. They see the substance we bring. It’s not about hugs and rainbows.

4. Give companies something they can’t get elsewhere

The fabric is what sells our client, but the data and the content we supply is what makes us sticky. I can go to a company that’s not used to looking at textiles this way. They’re used to this or that spec. I’ll say in addition to that, we’ll introduce you and your customers to the people whose lives are changed in our supply chain. That makes the social and economic impact real. One of the biggest problems for big brands is helping them find ways to be authentic even though they’re enormous.

5. Set your sales priorities

I can spend all my time selling to big fish. Those are much quicker deals. But if I’m only doing that, I’m not selling to whales. I’m not building the value of the company. Because if we’re not doing a million yards of fabric, what impact are we having? So we have a two-whale strategy. That’s what makes me optimistic. We only need a couple.

It takes time. One company that we’re working with started in May 2014. They gave us a couple of hard turnaround times to see if we could handle it. We did. Then it was focus groups with their customers to see if our product resonated well. And it did. Then you move into actual production for next season and hope to really hit the gas in 2017. That’s a whale.

Source: http://www.fastcompany.com/3052657/ignite-positive-change/thread-ceo-ian-rosenbergers-5-keys-to-strategic-partnerships


 A Pittsburgh-based startup that helps consumers nationwide make decisions about schools, colleges and neighborhoods, is raising capital to increase staff, visibility and new products.

Luke Skurman, CEO of Niche.com Inc., confirmed that the review site company has <a onclick="javascript:_gaq.push(['_trackPageview', '/out/www.sec.gov/Archives/edgar/data/1303152/000130315215000006/xslFormDX01/primary_doc.xml']);" href="http://www this link.sec.gov/Archives/edgar/data/1303152/000130315215000006/xslFormDX01/primary_doc.xml”>closed on$1 million toward a $5 million goal, its first fundraising effort since rebranding two years ago. Investors are a combination of private individuals, angel networks and venture capitalists, he said.

“The majority of that capital will be used to bulk up on sales and marketing and business development and continue to fortify our engineering and product teams,” Skurman said.

The company, which now employs 27, expects a 50 percent increase in staff a year from now. All hires will be local. Niche is based in Pittsburgh’s Shadyside neighborhood.

“The business is doing really well,” said Skurman, who founded the company as College Prowler back in 2002 when he was still a student at Carnegie Mellon University. “Traffic is up 150 percent, year-over-year, and we now have two new verticals.”

College Prowler originally produced guides to colleges based on reviews written by students at these schools, building a national following accumulating entrepreneurship awards and attracting prominent high-net-worth investors including FreeMarkets Founder Glen Meakem. The name was changed to Niche.com Inc. in 2013 so the company could diversify into new areas. By providing reviews and insights from everyday experts, Niche aims to help make choosing where to live or enroll a more transparent process.

The two new additions are Niche K-12, which covers schools, kindergarten through grade 12, and Niche Local, focused on cities, suburbs and neighborhoods.

Skurman is also a co-founder and chairman of Thrill Mill, a nonprofit incubator and accelerator.


The company’s name was incorrect in an earlier article.

Source: http://www.bizjournals.com/pittsburgh/news/2015/11/04/content-startup-raising-capital-increasing-staff.html

The Stork OTC Home Conception Aid Featured on The Doctors Show, October 9th, 2015

Rinovum® Women’s Health announced today that The Stork® OTC—the only home-use conception assistance device on the market cleared by the FDA for over-the-counter sales—was featured on a recent episode of the Emmy Award-winning daytime talk show The Doctors. The episode, showcasing innovative, medical products, aired Friday, October 9th, 2015.

Starting a family is one of the most important times in a couple’s life. For some, getting pregnant is easy; however, for approximately 7.3 million people it is not so simple: one in six US couples experience difficulty conceiving due to infertility1. The pathway to parenthood can be an extremely taxing time, both emotionally and financially, often leaving couples feeling out of control. The Stork OTC is an innovative device that offers couples a relaxed and private way of using cervical cap insemination – an established, effective conception technique previously available only by prescription – to help with becoming pregnant. It is the only FDA-cleared product that provides consumers a safe, easy way to perform this technique by themselves, at home.

“This product is $80, compared to if you go to your Doctor and your insurance doesn’t cover IVF, or any type of fertility treatment you could end up paying a lot. So it’s worth a shot…the whole idea is kind of like a modified version of the turkey baster…but what you’re doing that is different, is you’re putting this cervical cap in…and you let the sperm “marinate” at the cervix…It keeps everything right at the cervix to help increase your chances of getting pregnant,” said Dr. Rachael Ross, during the aired segment.

The Stork OTC uses a “condom-like” sheath for the collection of sperm and an easy-to-use “tampon-like applicator” which delivers the cervical cap of sperm close to the cervical opening. Cervical cap insemination has a recorded success rate of around 20%2,3, which is comparable to IUI – with recorded success rates between 16-21%4. Watch the full video on how The Stork OTC works here.

“The Stork OTC is an easy-to-use, logical, cost-effective way to take control and optimize your chances to conceive at home,” said Stephen Bollinger, President and CEO of Rinovum Women’s Health, and co-creator of the device. “This product has helped many couples get closer to their goal of building a family. We are excited to bring greater awareness to the many women and couples that are still trying.”

Who Can Use The Stork OTC?

The Stork OTC can help people optimize their chances of conceiving, including:

  • People who are trying to become pregnant.
  • Men diagnosed with low sperm count or motility issues.
  • Women diagnosed with an unfavorable vaginal environment (pH imbalance).
  • Couples trying to become pregnant without intercourse.
  • Couples who are not ready to take the next step in reproductive treatment such as IUI or IVF.




The Stork OTC is available for purchase at select retailers nationwide, and online. Visitwww.storkotc.com for online sales and store locations. The device was cleared by the FDA for over-the-counter sales in July 2014, and made available to the market in September of 2014. The product is available for sale as The Stork in the United Kingdom, Australia, and Canada.

1National Institutes of Health, National Institute of Child Health and Human Development;<a onclick="javascript:_gaq.push(['_trackPageview', '/out/cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.nichd.nih.gov%2Fhealth%2Ftopics%2Finfertility%2Fconditioninfo%2FPages%2Fcommon.aspx&esheet=51206945&newsitemid=20151022005198&lan=en-US&anchor=http%3A%2F%2Fwww.nichd.nih.gov%2Fhealth%2Ftopics%2Finfertility%2Fconditioninfo%2FPages%2Fcommon.aspx&index=3&md5=a8144db63c6e927a25c529328400848a']);" href="http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.nichd.nih.gov%2Fhealth%2Ftopics%2Finfertility%2Fconditioninfo%2FPages%2Fcommon.aspx&esheet=51206945&newsitemid=20151022005198&lan=en-US&anchor=http%3A%2F%2Fwww.nichd.nih important source.gov%2Fhealth%2Ftopics%2Finfertility%2Fconditioninfo%2FPages%2Fcommon.aspx&index=3&md5=a8144db63c6e927a25c529328400848a” rel=”nofollow”>http://www.nichd.nih.gov/health/topics/infertility/conditioninfo/Pages/common.aspx
2 ”Therapeutic donor insemination: A prospective randomized trial of fresh versus frozen sperm.” Leslee L. Subak, MD, G. David Adamson, MD, Nancy L. Boltz, RNC. American Journal of Obstetrics & Gynecology, Volume 166, Issue 6, Part 1, June 1992.http://www.ncbi.nlm.nih.gov/m/pubmed/1615966/
3 ”The cervical cap for home artificial insemination.” Corson SL, Batzer FR, Otis C, Fee, D. Journal of Reproductive Medicine, May 1986; 31(5)349-52.http://www.ncbi.nlm.nih.gov/m/pubmed/3746786/
4 American Society for Reproductive Medicine:http://www.reproductivefacts.org/FACTSHEET_Intrauterine_Insemination_IUI/

Source: http://www.reuters.com/article/pa-rinovum-womens-health-idUSnBw225198a+100+BSW20151022#QqG5UcDocmTJYxxQ.97

HOUSTON, Sept. 30, 2015 /PRNewswire-USNewswire/ — For the first time ever in the state of Texas, the team at Memorial Hermann Heart & Vascular Institute-Texas Medical Center used the advanced technology of a minimally-invasive machine called the Hemolung Respiratory Assist System (RAS) to help save the life of an 18-year-old Texas boy. Its historic use at Memorial Hermann Heart & Vascular Institute-TMC is only the fourth time the machine has been used in the United States, helped remove carbon dioxide fromUriel Alvarado’s blood in a process called respiratory dialysis.

Hemolung RAS is the first fully-integrated Respiratory Dialysis® system. Similar to the more common renal dialysis which removes waste from the body in order to ensure a safe level of chemicals in the blood in case of kidney failure, the Hemolung RAS uses advanced technology to support the lungs by removing carbon dioxide and delivering oxygen directly to the blood by using a circuit outside the body and a small venous catheter. The use of the machine allows the lungs to rest and heal.

Doctors recently discovered that Alvarado, who has a history of testicular cancer, had a mass in his chest. Due to the mass, he had to have a lung removed in June 2015. While recovering, Alvarado had abnormal levels of carbon dioxide in his blood that put him at high risk of respiratory arrest, which could have been fatal.

“Unfortunately, Uriel’s struggle with cancer and recent lung removal meant the anatomy of his heart was slightly distorted and he was not a good candidate for conventional extracorporeal membrane oxygenation (ECMO), a device that provides support to those whose lungs and heart are not able to support the body properly,” said Keshava Rajagopal, M.D., Ph.D., cardiothoracic and vascular surgeon with Memorial Hermann Heart &Vascular Institute-TMC’s Center for Advanced Heart Failure and assistant professor of cardiothoracic surgery at UTHealth Medical School. “Lung diseases manifest in different ways in different people, and Uriel’s problem was more related to high carbon dioxide rather than low oxygen. It was considered an emergency situation and we were lucky to have rapid access to the Hemolung RAS.”

Alvarado’s medical team knew they needed to act quickly.

“Before using the Hemolung RAS, we had exhausted all options,” said Bindu Akkanti, M.D., Medical Director of the Heart Failure Intensive Care Unit with Memorial Hermann Heart &Vascular Institute-TMC and assistant professor of critical care medicine at UTHealth. “The patient improved within hours of being on the device; it is a true advancement in medicine. We are evaluating new technologies at the bedside every day, and the success of this patient is the result of excellent multidisciplinary efforts between the intensive care physicians and the other members of the ECMO service, including the cardiothoracic surgeons and the heart failure experts.”

After three days on the device, Alvarado saw drastic improvements and was able to be removed from the machine completely and continue his recovery from the comfort of his own home. Now, when he isn’t taking classes at South Texas College in McAllen, Texas, Alvarado has returned to his passion of mixing music sertraline 25 mg. He is also working to pursue his new dream of becoming a nurse someday.

“Uriel was truly inspired by the clinical team who helped save his life,” said Maria Alvarado, Uriel’s mother. “Becoming a nurse is a way he feels he can give back to those who might be suffering like he was. At only 18 years old, Uriel still has his whole life ahead of him. There’s no telling what all we could see him do.”

Source: http://www.prnewswire.com/

Cost-per-impression ad pricing is so yesterday. A New York City-based ad tech shop is today launching a limited beta of what it describes as the first-ever cost-per-second (CPS) platform for ads.

Sled Mobile’s Parsec platform is based on the idea that the key thing display advertisers want is user attention. Time spent with the ad, CEO and founder Marc Guldimann told me, is “a proxy for attention.”

While direct response advertisers have performance standards like making a sale or getting a form filled in, he noted that the key performance indicator for brand advertising is attention.

The new platform, with a pricing of one cent per second per device, is immune to questions about whether the ad is viewable, he said. That’s because the meter doesn’t start running until at least half the ad is on the screen for at least one second — the Media Research Center’s (MRC) basic standard for ad viewability.

As for the other digital ad bugaboo — fraudulent traffic generated by software bots — he pointed out that Parsec is integrated with the anti-fraud service from Moat. Although non-human traffic is always possible, he admitted, it’s likely to be low because the unique Sled format requires touch and gesture — two actions that are harder for bots to imitate. At least for now.

The Sled format is, in Guldimann’s description, “behaviorally native.” As a user scrolls down to read an article or news feed, the ad scrolls up an overlay, as shown in this gallery of examples. A user can dismiss the ad by pushing it down or scroll it up, view it, and then keep scrolling past it when done.

“You don’t have to change the mode you’re in,” he said, since the user views the ad as part of her continuous scrolling action — just like the same-mode ads in TV, search, and print. Within Sled, ads can have autoplay video, fullbleed video, static images, product carousels, surveys, and other features.

Guldimann said no one else has this “politely interruptive” format, which was launched when the company started at the end of last year.

Ten million seconds

He noted that mobile ad agency Celtra has an “inter-scroller” ad that is not placed in an overlay, so it breaks the content into before- and after-the-ad pieces. Ad shop Yieldmo offers a hyperscroller, but that’s right in the content stream — also not an overlay.

Sled is the first to use CPS for this kind of platform and attention-optimized ad format, he said. Chartbeat has a CPS tool that is not supported by a platform, he added, and a Brazil-based company called Web Spectator sells by CPS.

But, Guldimann noted, they use “adjacent ads” like banners, “sprinkled all over a web page [so] you can’t be sure of user attention,” since time spent on the screen could be driven by the content, not the ad. Sled would like the MRC to establish CPS as a valid standard, he said, although Sled Mobile is not formally submitting it.

Currently, the platform only supports mobile web, although Guldimann told me it will be able to handle in-app ads within a few months. Apple’s new iOS 9 supports web ad blockers, and he acknowledged that “some [blockers] will block us.”

Two advertisers have signed up so far for the new CPS platform — the San Antonio Board of Tourism and an unnamed client. An ongoing study with Microsoft Research is helping to measure this format’s appeal to users, as well as advertisers’ response to the CPS pricing.

Guldimann said a time-based pricing mechanism means that the advertiser and publisher ecosystem will emphasize ads that hold user attention. When I pointed out that time spent on the ad could reflect the ad’s complexity, he suggested that results from straightforward ads will help generate insight into what best attracts, and keeps, user attention.

While the Parsec CPS platform is only supporting Sled’s unique format, Guldimann said it could support any mobile ad format that meets the same attention requirements: fully interruptive so there’s no doubt the user is watching that ad, and controlled by the user.

With the new platform, an advertiser will say they want to buy, say, ten million seconds sertraline 100mg. Sled creates the ad, and then buys space through a direct sale on the mobile sites of publishers in its network, which include AOL and Rolling Stone.

The older Sled platform serves that same format, but on a CPM — cost per thousand impressions — basis. For that platform, Sled Mobile creates and serves the ads, but the publishers sell their space directly. It has supported about 140 campaigns since the end of last year.

Source: http://venturebeat.com/2015/09/21/ad-tech-shop-sled-mobile-launches-a-platform-that-prices-ads-by-time/

Stephen Bollinger had a simple idea for a company: Make it easier and less costly for couples struggling with infertility to conceive at home.

The concept has spawned a growing business, Rinovum Women’s Health. The Monroeville company’s first product, the Stork, received clearance from the Food and Drug Administration last year for over-the-counter sales and is available in about 3,000 CVS pharmacies.

The device, which helps women increase the odds of pregnancy by delivering sperm to the cervix, should be on the shelves of more than 5,000 Walgreens pharmacies and an additional 2,000 CVS stores by early next year, Bollinger said.

“The whole idea is to simplify medical technology so it can be used in a couple’s home,” he said. “Privacy, that’s where the Stork really adds value.”

The device, which retails for $79, mimics a type of artificial insemination performed in a doctor’s office or other clinical setting that can cost hundreds of dollars.

“This is a good first step, a bridge for the patients who are having trouble getting pregnant,” said Dr. Michael Pelekanos, an obstetrician and gynecologist with East Suburban OB/GYN Associates in Monroeville.

Pelekanos is a consultant and adviser to Rinovum who is organizing clinical studies of the Stork.

“This is a stop-gap measure between a major medical investigation and just standard intercourse,” he said. “I believe this will enhance fertility.”

Infertility in the United States has nearly doubled in the past 35 years, from one-in-10 couples in 1980 having difficulty conceiving to one-in-six, or an estimated 7.3 million couples, today.

The increase, driven up by women waiting longer to have children and lower sperm counts in men, has spawned a huge industry.

The market for infertility services and devices is more than $3.5 billion and expected to reach $4.3 billion by 2018, according to research firm Marketdata. About $1.9 billion of that is spent on in vitro fertilization, a lab procedure with an average cost of $12,000.

Rinovum positions the Stork as a significantly less costly alternative, which should be tried before going to a doctor.

“But it’s not a silver bullet,” Bollinger said. “If there’s a medical problem (that prevents pregnancy), we can’t help.”

Bollinger, a Delmont native, attended the Military Academy at West Point, fought in the first Gulf War and had a career in the life sciences industry. He started and sold two companies in Massachusetts before returning to the region in 2008 to help coach startup companies at the Pittsburgh Life Sciences Greenhouse see post.

A year later, the itch to run his own company returned, he said. “At some point, I got sick of coaching and wanted to get back to doing.”

He knew he wanted to pursue a solution to a health care problem that he could market directly to consumers and remembered the difficulty that he and his wife had trying to conceive their first child in the early 1990s. Bollinger was aware that it was an increasingly common problem.He formed Rinovum in 2009 and started developing early versions of the Stork. In 2013, it received approval from the FDA for prescription-only sales, which led to sales of “a couple thousand dollars a week,” he said.

A major turning point happened in September when the FDA cleared the Stork for over-the-counter sales. Rinovum also started selling the device in Canada and the United Kingdom.

With the addition of more pharmacies selling the Stork, Bollinger said he expects Rinovum’s revenue to grow to at least $12 million by the end of 2016, up from $800,000 in 2014 and an expected $2.4 million this year.

Rinovum is exploring how to expand sales to more countries in Europe and to Asia.

“Infertility in China is even bigger than in the U.S.,” Bollinger said.

Alex Nixon is a staff writer for Trib Total Media. He can be reached at 412-320-7928 or anixon@tribweb.com.

Read more: http://triblive.com/business/headlines/8930319-74/rinovum-stork-bollinger#ixzz3jMoyJjva
Follow us: @triblive on Twitter | triblive on Facebook

Source: http://triblive.com/

Technology developed at the University of Pittsburgh and licensed by ALung enhances the performance of artificial lung devices, paving the way for the development of less invasive respiratory support systems.

Pittsburgh, PA (August 3, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today announced the publication of new data by University of Pittsburgh researchers on two groundbreaking technologies it has previously licensed from the University. The new technologies, which help enhance the performance of artificial lung devices, were developed by Dr. William Federspiel, Professor of Bioengineering at the University of Pittsburgh, and his team in the Medical Devices Laboratory of the McGowan Institute for Regenerative Medicine. Dr. Federspiel is also a co-founder of ALung Technologies.

Artificial lung devices are used to support patients with lung failure. They work by passing a patient’s blood over an artificial membrane which removes carbon dioxide and delivers oxygen to the blood, independently of the native lung. While today’s artificial lung technology is very good, a clinical need still exists for more efficient, minimally invasive devices. The new techniques developed by Dr. Federspiel use a combination of two biochemical approaches that work synergistically to more than double the rate of carbon dioxide removal across the artificial lung membrane. The work of Dr. Federspiel’s team was recently published in the journals Acta Biomaterialia and the Journal of Material Science: Materials in Medicine, designated in the latter as an “Editor’s Choice” paper.

ALung’s license agreement with the University Pittsburgh for this new technology includes two pending patent applications. “These novel technologies fit nicely within our broader intellectual property portfolio of methods for enhancing gas exchange,” said Peter DeComo, ALung Chairman and CEO. “The continued refinement of these techniques, as highlighted in the new publications, help pave the way for the future development of more effective artificial lung devices for the millions of patients with acute and chronic lung failure. We offer Dr. Federspiel and his team our congratulations on their most recent publications.”

ALung’s Hemolung Respiratory Assist System, a minimally invasive extracorporeal CO2removal system for treating patients with acute respiratory failure, also incorporates technology licensed from the University of Pittsburgh.

About ALung Technologies

ALung Technologies, Inc. is a privately-held Pittsburgh-based developer and manufacturer of innovative lung assist devices. Founded in 1997 as a spin-out of the University of Pittsburgh, ALung has developed the Hemolung RAS as a dialysis-like alternative or supplement to mechanical ventilation. ALung is backed by individual investors and venture firms including Allos Ventures, Birchmere Ventures and West Capital Advisors, LLC.

For more information about ALung and the Hemolung RAS, visit www.alung.com.

This press release may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well as risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with regulatory approval processes, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time, but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

Source: ALung Technologies

San Francisco, CA, May 11, 2014— Gemmus Pharma, Inc., a privately-held pharmaceutical company developing innovative therapies to treat influenza, announced today that its Investigational New Drug Application (IND) for GP1681, the company’s lead product candidate, has been accepted by the U.S. Food and Drug Administration (FDA) and is now active. Gemmus expects to begin a Phase 1 clinical trial in Q2 2015 to identify suitable doses of GP1681 in healthy adults. “We are very pleased to receive the Safe to Proceed status and we look forward to starting clinical trials for GP1681” said William Guilford, PhD., President and a co-founder of Gemmus. “We believe that our immune system-based approach to treating influenza should allow for a faster return by patients to normal activity than is possible with existing therapies.”

In addition to its IND approval, Gemmus has been granted a patent covering the use of GP1681 in combination with antiviral drugs (US patent). “This extension of our patent portfolio further supports our clinical development plans for GP1681.” said William Holstein, Senior Vice President, Business Development of Gemmus.

About GP1681

GP1681 is being developed to alleviate influenza symptoms by reducing, but not eliminating, the viral-induced, exaggerated cytokine response. The potential benefit of treatment with GP1681 is supported by the results in mouse models of influenza. This host-targeted therapy has the potential advantage of being able to treat any influenza virus subtype when flu-symptoms are present without concern for the development of viral resistance.

About Gemmus

Gemmus is a privately held pharmaceutical company focused on the development of innovative products for the treatment of infectious diseases by modulating the host response to the disease. Gemmus was founded in 2007 to develop EP2 and EP4 agonists for the treatment of influenza and in-licensed technology from a major pharmaceutical company. The company has applied for and received an SBIR(NIH) and a QTDP competitive grant. Gemmus is a member of the QB3 network, a San Francisco Bay Area life sciences incubator associated with the University of California – San Francisco (UCSF). The company is currently seeking suitable corporate partners for further clinical development of GP1681 and for expansion into additional viral indications. For more information and corporate background, please visit: www.gemmuspharma.com.

Forward Looking Statements

Statements included in this press release that are not a description of historical facts may be forward looking statements. The inclusion of forward looking statements should not be regarded as a representation by Gemmus that any of its plans will be achieved. Actual results may differ materially from those anticipated or set forth in this press release due to the risks and uncertainties inherent in Gemmus’ business including, without limitation, statements about difficulties or delays in developing, obtaining regulatory approval, manufacturing and commercializing its products, unexpected performance or side effects of its products, the scope and validity of its products’ patent protection, competition from other companies and its ability to obtain additional financing to support its operations. All forward looking statements are qualified in their entirety by this statement and Gemmus undertakes no obligation to revise or update this press release to reflect events or circumstances occurring after the date hereof.

Source: Gemmus Pharma

Pittsburgh, PA (January 14, 2015) – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today announced that it has received marketing clearance from the Australian Therapeutic Goods Administration (TGA) for its Hemolung Respiratory Assist System (RAS). ALung has partnered with Medtel Australia Pty Ltd to distribute the Hemolung RAS which is the first ECCO2R system to be approved and commercially available in Australia.

The Hemolung RAS is a dialysis-like alternative or supplement to mechanical ventilation for treating patients with acute respiratory failure, including those suffering from acute exacerbation of chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS). The TGA approval allows the Hemolung RAS to be utilized in over 75 hospitals across Australia with level 3 intensive care units. The device is also cleared for use in Europe and Canada.

ALung has partnered with Medtel Australia Pty Ltd to distribute the Hemolung RAS. Celebrating 50 years of operation in 2015, Medtel is a long established distributor of innovative medical products, providing sales and service from offices in each mainland state of the country. Andrew Lehmann, Managing Director of Medtel Australia stated, “Medtel is most pleased to gain this key regulatory step in making the Hemolung technology available to the intensive care clinicians in Australia. The Hemolung RAS is viewed as an innovative and market disruptive technology with the opportunity to provide patients with better outcomes and fewer lung complications. Medtel looks forward to partnering with ALung to promote and support the Hemolung product.”

Obtainment of TGA approval for the Hemolung RAS took approximately 12 months. Prior to receipt of the TGA approval, three Australian hospitals had the opportunity to evaluate the Hemolung RAS under a special Authorized Prescriber program to access innovative medical devices. Dr. Hergen Buscher, Staff Specialist for Intensive Care Medicine at St. Vincent Hospital Sydney who participated in this program, commented, “Minimally invasive ECCO2R devices like the Hemolung RAS have the potential to change the way we ventilate our critically ill patients by avoiding some of the life threatening side effects of mechanical invasive ventilation.”

“We are grateful for the support of Medtel, the Australian intensive care community, and the TGA as we worked through this approval process,” said Nicholas Kuhn, ALung President and Chief Business Officer. “We are very excited to make the Hemolung RAS available to physicians all across Australia as they seek to optimize the care of their most critically ill patients.”

About ALung Technologies
ALung Technologies, Inc. is a privately-held Pittsburgh-based developer and manufacturer of innovative lung assist devices. Founded in 1997 as a spin-off from the University of Pittsburgh, ALung has developed the Hemolung RAS as a dialysis-like alternative or supplement to mechanical ventilation. ALung is backed by individual investors and venture firms including Allos Ventures, Birchmere Ventures and West Capital Advisors, LLC.

For more information about ALung Technologies and the Hemolung RAS, visit www.alung.com.

About Medtel Pty Ltd
Medtel Pty Limited is a supplier of high-end technology products and services to the medical and allied health care industry, with sales and service offices located across Australia and New Zealand.

Established in 1965, Medtel is part of The Getz Group of Companies, an international marketing and services company committed to excellence and with over 150 offices in 49 countries and 6 continents around the world. The Getz Group origins date back to as early as 1852.

Partnering with prominent global industry leaders, Medtel offers the latest in medical technology and is driven by the mission to make lives better through quality products and exceptional service.

For more information about Medtel, and for interest in the Hemolung RAS in Australia, visit http://www.medtel.com.au/.

This press release may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well as risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with regulatory approval processes, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time, but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

Source: ALung Technologies


Search for

Contact Us

BlueTree Venture Fund
P.O. Box 1323
Wexford, PA 15090